Tumor Microenvironment Gene Engineering with LOAd703 in Patients with Solid Malignancies: LOKON002 Phase I/IIb Clinical Trial
Authors:
- Amanda HahnAHAmanda Hahn
- Sandra IrenaeusSISandra Irenaeus
- Linda C. SandinLSLinda C. Sandin
- Clara NordströmCNClara Nordström
- Jessica WentheJWJessica Wenthe
- Tanja LövgrenTLTanja Lövgren
- Emma ErikssonEEEmma Eriksson
- Salem AlsaqalSASalem Alsaqal
- Simon PahnkeSPSimon Pahnke
- Anders SundinAnders Sundin
- Justyna Leja JarbladJJJustyna Leja Jarblad
- Maria Gustafsson LiljeforsMLMaria Gustafsson Liljefors
- 1 June 2026
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (15) , OF1-OF12
Abstract
Purpose: Patients with advanced cancer have a poor prognosis and need for novel treatments. LOAd703 is a tumor microenvironment (TME) gene engineering viral vector encoding genes targeting the CD40 and 4-1BB pathways. In this study, tolerability (primary endpoint), response activity, and the capacity to inflame the TME were evaluated. Patients and Methods: In an open-label, single-arm phase I/IIb clinical trial (NCT03225989), a maximum of eight intratumoral injections of LOAd703 were administered biweekly, combined with a gemcitabine-based chemotherapy regimen, either standard-of-care treatment or conditioning gemcitabine if no standard options were available. Dose escalation followed a standard 3 + 3 design (phase I) and, to optimize dosage, the two highest dose levels were expanded in phase II. Results: Forty-one patients were enrolled with pancreatic (n = 29), colorectal (n = 5), ovarian (n = 4), and biliary cancers (n = 3). Treatment was generally well tolerated. The most common LOAd703-related adverse events were pyrexia (76%), chills (39%), and fatigue (34%), mostly grade 1 to 2. The overall response rate (ORR) was 0 in the LOAd703 dose cohort 5 × 1010 viral particles (VP), 25% in 1 × 1011 VP, and 12% in 5 × 1011 VP. All patients with an objective response had pancreatic cancer and received first-line treatment (ORR, 35%). The TME showed a significant upregulation of Th1 immunity biomarkers at week 13 posttreatment initiation. Conclusions: TME gene engineering using LOAd703 inflamed immune cold tumors and was followed by long-term stabilized disease in several patients. Further evaluation of LOAd703 together with chemotherapy and/or checkpoint inhibitors is warranted.Keywords
All Related Versions
Funding Information
- Cancerfonden (22 2342 Pj)
- Vetenskapsrådet (2024-03471)
- Stiftelsen Onkologiska Klinikens i Uppsala Forskningsfond
- Lokon Pharma AB
- Cancerfonden (23 2698 Pj01)
- Barncancerfonden (PR2021-0061)
This publication has 36 references indexed in Scilit:
- Fc-optimized CD40 agonistic antibody elicits tertiary lymphoid structure formation and systemic antitumor immunity in metastatic cancerCancer Cell, 2025
- LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): results from arm 1 of a non-randomised, single-centre, phase 1/2 studyThe Lancet Oncology, 2024
- CCL5 might be a prognostic biomarker and associated with immuno-therapeutic efficacy in cancers: A pan-cancer analysisHeliyon, 2023
- Clinical Activity of Olvimulogene Nanivacirepvec–Primed Immunochemotherapy in Heavily Pretreated Patients With Platinum-Resistant or Platinum-Refractory Ovarian CancerJAMA Oncology, 2023
- Immune priming using DC- and T cell-targeting gene therapy sensitizes both treated and distant B16 tumors to checkpoint inhibitionMolecular Therapy-Oncolytics, 2022
- Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non–muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical TrialEuropean Urology, 2021
- Immune monitoring in mesothelioma patients identifies novel immune-modulatory functions of gemcitabine associating with clinical responseEBioMedicine, 2021
- Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibitionCell, 2021
- Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trialThe Lancet Oncology, 2020
- Changes in the immune cell population and cell proliferation in peripheral blood after gemcitabine-based chemotherapy for pancreatic cancerClinical and Translational Oncology, 2013